Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2071039 | 0.89 | CRHR1 (0.54) | CRHR1POLBTSHRMAPTGAA | |
| SCHEMBL2071464 | 0.85 | CRHR1 (0.53) | CRHR1TSHRMAPTGAAALDH1A1 | |
| SCHEMBL12775294 | 0.82 | CRHR1 (0.67) | CRHR1MAOAMAOBMAPT | |
| SCHEMBL2072641 | 0.80 | CRHR1 (0.66) | CRHR1TSHRMAPTALDH1A1HIF1A | |
| SCHEMBL2072594 | 0.78 | CRHR1 (0.46) | CRHR1TSHRMAPTGAAALDH1A1 | |
| SCHEMBL2070177 | 0.77 | CRHR1 (0.49) | CRHR1GAA | |
| SCHEMBL2072342 | 0.76 | CRHR1 (0.57) | CRHR1POLBGAAHIF1ASMN1; SMN2 | |
| SCHEMBL2071199 | 0.75 | CRHR1 (0.52) | CRHR1MAOAMAOBPOLBADORA1 | |
| SCHEMBL2073108 | 0.74 | CRHR1 (0.63) | CRHR1ALDH1A1 | |
| SCHEMBL2070099 | 0.73 | CRHR1 (0.62) | CRHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | CRHR1 1/4885MAOA 161/4885MAOB 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.